贝叶斯预测模型平均方法用于纵向与生存数据的联合建模:在免疫肿瘤学临床试验中的应用
针对免疫肿瘤学试验中纵向生物标志物与生存数据的联合建模,提出使用贝叶斯留一交叉验证预测密度的贝叶斯预测模型平均(BPMA)方法,以处理模型不确定性并考虑个体与时间依赖性;通过模拟研究评估预测准确性(校准与区分能力),并将其应用于晚期卵巢癌免疫肿瘤学临床试验以讨论优缺点。
要点
- 提出BPMA方法,用贝叶斯留一交叉验证预测密度对多个候选联合模型进行平均。
- 模拟研究评估BPMA的预测准确性,包括校准能力和区分能力。
- 将BPMA应用于晚期卵巢癌免疫肿瘤学临床试验,讨论其优势与局限性。
核心结论
- 提出贝叶斯预测模型平均(BPMA)方法,利用贝叶斯留一交叉验证预测密度考虑预测的个体特异性和时间依赖性。
研究设计与样本
- 方法学研究,通过广泛的模拟研究评估所提出BPMA方法的运行特征。
- 并将该方法应用于一项晚期卵巢癌患者的免疫肿瘤学临床试验。
主要发现
- 模拟研究从预测准确性(即校准能力和区分能力)方面检验了BPMA方法的运行特征。
- 通过应用于晚期卵巢癌免疫肿瘤学临床试验,讨论了所提出方法的优势与局限性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In immuno-oncology clinical trials, multiple immunological biomarkers are usually examined over time to comprehensively and appropriately evaluate the efficacy of treatments. Because predicting patients' future survival statuses on the basis of such recorded longitudinal information might be of great interest, joint modeling of longitudinal and time-to-event data has been intensively discussed as a toolkit to implement such a prediction. To achieve a desirable predictive performance, averaging over multiple candidate predictive models to account for the model uncertainty might be a more suitable statistical approach than selecting the single best model. Although Bayesian model averaging can be one of the approaches, several problems related to model weights with marginal likelihoods have been discussed. To address these problems, we here propose a Bayesian predictive model averaging (BPMA) method that uses Bayesian leave-one-out cross-validation predictive densities to account for the subject-specific and time-dependent nature of the prediction. We examine the operating characteristics of the proposed BPMA method in terms of the predictive accuracy (ie, the calibration and discrimination abilities) in extensive simulation studies. In addition, we discuss the strengths and limitations of the proposed method by applying it to an immuno-oncology clinical trial in patients with advanced ovarian cancer.
引用
- Yao Z, Morita S, Nishida S, et al. Bayesian predictive model averaging approach to joint longitudinal-survival modeling: Application to an immuno-oncology clinical trial. Stat Med. 2023. PMID: 37705361. doi:10.1002/sim.9897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。